Table 2 Treatment-related adverse events for all cohorts
SOC | CTCAE term | All subjects (n = 31) | |||
|---|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Any grade | ||
Patients with events | All terms | 8 (25.8) | 4 (12.9) | 3 (9.7) | 15 (48.4) |
Blood and lymphatic system disorders | Anemia, n (%) | 5 (16.1) | 1 (3.2) | 0 | 6 (19.4) |
Gastrointestinal disorders | Nausea, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) |
General disorders and administration site conditions | Chills, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) |
Edema limbs, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) | |
Fatigue, n (%) | 3 (9.7) | 0 | 0 | 3 (9.7) | |
Fever, n (%) | 3 (9.7) | 0 | 0 | 3 (9.7) | |
Flu like symptoms, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) | |
Non-cardiac chest pain, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) | |
Investigations | Blood bilirubin increased, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) |
Investigations—Other, interleukin 2 receptor increased, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) | |
Lymphocyte count decreased, n (%) | 3 (9.7) | 1 (3.2) | 0 | 4 (12.9) | |
Neutrophil count decreased, n (%) | 2 (6.5) | 3 (9.7) | 2 (6.5) | 7 (22.6) | |
Platelet count decreased, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) | |
WBC decreased, n (%) | 3 (9.7) | 3 (9.7) | 0 | 6 (19.4) | |
Musculoskeletal and connective tissue disorders | Back pain, n (%) | 0 | 0 | 1 (3.2) | 1 (3.2) |
Pain in extremity, n (%) | 1 (3.2) | 1 (3.2) | 0 | 2 (6.5) | |
Nervous system disorders | Dizziness, n (%) | 1 (3.2) | 1 (3.2) | 0 | 2 (6.5) |
Dysesthesia, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) | |
Headache, n (%) | 1 (3.2) | 0 | 0 | 1 (3.2) | |
Paresthesia, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) | |
Vascular disorders | Hypertension, n (%) | 0 | 1 (3.2) | 0 | 1 (3.2) |
Hypotension, n (%) | 2 (6.5) | 0 | 0 | 2 (6.5) | |